On 18 October 2025, Omeros Corporation announced the publication of a peer‑reviewed manuscript in Blood Advances that presents survival outcomes for adult patients with transplant‑associated thrombotic microangiopathy (TA‑TMA) treated with narsoplimab across both the pivotal clinical trial and the global expanded access program.
The manuscript reports significant, multifold reductions in mortality risk across the pivotal trial and expanded access cohorts, individually and pooled, compared to a well‑matched external control group, and notes no safety signals of concern.
The publication is available online and underscores the robust clinical evidence supporting narsoplimab, which is currently under review by the FDA and EMA and has received breakthrough therapy and orphan drug designations for TA‑TMA.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.